Buspirone
Indications
Information about indications was extracted from the indications and usage sections of the labels.
| Side effects: | 24 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 48 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 130 |
| Source: | Health Canada |
|---|
| Side effects: | 81 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 81 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 103 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 102 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 104 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 106 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 110 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 111 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 120 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 122 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 127 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 128 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 129 |
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 130 |
| Source: | FDA Structured Product Label |
|---|
Color scheme:
standard – alternative
|
|
|
100%
|
|
|
|
75%
|
|
|
|
50%
|
|
|
|
10%
|
|
|
|
frequent (1% to 100%)
|
|
|
|
infrequent (0.1% to 1%)
|
|
|
|
rare (<0.1%)
|
|
|
|
postmarketing
|
|
|
|
0%
|
|
|
|
no frequency information
|
|
|
|
not found on label
|